Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 2/20 | 0.56 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.56 |
| ▸ | ACE | P12821 | 1/20 | 0.56 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.53 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.51 |
| ▸ | PPARA | Q07869 | 6/20 | 0.49 |
| ▸ | PPARG | P37231 | 5/20 | 0.49 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.49 |
| ▸ | ITGAV | P06756 | 1/20 | 0.49 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.49 |
| ▸ | CTSS | P25774 | 7/20 | 0.48 |
| ▸ | CTSK | P43235 | 6/20 | 0.48 |
| ▸ | CTSB | P07858 | 2/20 | 0.48 |
| ▸ | FPR2 | P25090 | 1/20 | 0.48 |
| ▸ | PPARD | Q03181 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28502892 | 0.91 | ACE (0.54) | ITGA4ITGB7ACEITGB3ITGA2B | |
| SCHEMBL2675545 | 0.90 | LDHA (0.58) | ITGA4ITGB7ACEITGB3ITGA2B | |
| SCHEMBL3814635 | 0.90 | LDHA (0.58) | ITGA4ITGB7ACEITGB3ITGA2B | |
| SCHEMBL29726545 | 0.90 | LDHA (0.58) | ITGA4ITGB7ACEITGB3ITGA2B | |
| SCHEMBL21639310 | 0.89 | ACE (0.59) | ITGA4ITGB7ACEITGB3ITGA2B | |
| SCHEMBL21639309 | 0.89 | ACE (0.59) | ITGA4ITGB7ACEITGB3ITGA2B | |
| SCHEMBL28921935 | 0.88 | GRB2 (0.52) | ITGA4ITGB7ACEITGB3ITGA2B | |
| SCHEMBL18918277 | 0.88 | GRB2 (0.52) | ITGA4ITGB7ACEITGB3ITGA2B | |
| SCHEMBL15432845 | 0.88 | GRB2 (0.52) | ITGA4ITGB7ACEITGB3ITGA2B | |
| SCHEMBL16448094 | 0.87 | PTPN1 (0.57) | ITGA4ITGB7ACEITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2872157-B1 | CONJUGATES OF CELL BINDING MOLECULES WITH CYTOTOXIC AGENTS | HANGZHOU DAC BIOTECH CO LTD (CN) | 2020-01-22 | — | — | EP | disclosed |
| US-20170157262-A1 | CONJUGATES OF CELL BINDING MOLECULES WITH CYTOTOXIC AGENTS | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2017-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170157262-A1 | CONJUGATES OF CELL BINDING MOLECULES WITH CYTOTOXIC AGENTS | CD4, CD2, CD47 | ITGA4 718/4885ITGB7 343/4885ACE 4787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.